Epitomee Medical Ltd (TLV:EPIT)
Israel · Delayed Price · Currency is ILS · Price in ILA 400.00
0.00 (0.00%)
Sep 10, 2026, 5:24 PM IDT
Epitomee Medical Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -9.88 | -8.61 | -1.46 | -5.68 | -15.39 | -11.52 |
Depreciation & Amortization | 1.23 | 1.03 | 0.45 | - | 0.36 | 0.24 |
Asset Writedown & Restructuring Costs | - | - | -6.97 | - | - | - |
Stock-Based Compensation | 0.43 | 0.56 | 0.61 | - | 1.54 | 1.51 |
Other Operating Activities | 0.33 | -0.92 | -0.53 | -2.24 | 4.38 | 2.7 |
Change in Accounts Receivable | -0.16 | 0.11 | -0.13 | - | 0.17 | -0.24 |
Change in Inventory | -0.88 | -0.45 | -0.02 | - | - | - |
Change in Accounts Payable | 0.51 | 0.63 | -0.23 | - | -0.83 | 1.56 |
Change in Other Net Operating Assets | 0.28 | - | - | - | 0.36 | - |
Operating Cash Flow | -8.14 | -7.66 | -8.29 | -7.92 | -9.42 | -5.76 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -1.55 | -1.83 | -4.62 | -4.07 | -3.7 | -0.4 |
Investment in Securities | 0.03 | 5.5 | 12.85 | -9.01 | -9.59 | 15.58 |
Other Investing Activities | 0.41 | 0.6 | 1.95 | 0.86 | 0.17 | -0.05 |
Investing Cash Flow | -1.11 | 4.27 | 10.18 | -12.22 | -13.12 | 15.13 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | - | -0.67 | -0.52 | -0.5 | -0.33 | -0.22 |
Lease Payments | -0.76 | -0.67 | -0.52 | -0.5 | -0.33 | -0.22 |
Net Debt Issued (Repaid) | -0.76 | -0.67 | -0.52 | -0.5 | -0.33 | -0.22 |
Issuance of Common Stock | 0.09 | 0.06 | 0.01 | 0.04 | - | 52.3 |
Other Financing Activities | - | - | - | - | - | -1.97 |
Financing Cash Flow | -0.67 | -0.61 | -0.51 | -0.45 | -0.33 | 50.11 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 0.24 | 1.09 | -0.44 | 0.28 | -5.49 | - |
Net Cash Flow | -9.68 | -2.92 | 0.94 | -20.32 | -28.36 | 59.49 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -9.69 | -9.49 | -12.91 | -12 | -13.12 | -6.16 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -1245.50% | -4455.87% | - | -119.96% | - | - |
Free Cash Flow Per Share | -0.32 | -0.32 | -0.43 | -0.40 | -0.45 | -3.50 |
Levered Free Cash Flow | -7.79 | -7.41 | -4.66 | -7.4 | -9.05 | -4.52 |
Unlevered Free Cash Flow | -6.94 | -6.88 | -4.54 | -7.37 | -9.05 | -2.83 |
Free Cash Flow After Leases | -10.45 | -10.16 | -13.43 | -12.49 | -13.45 | -6.38 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Change in Working Capital | -0.26 | 0.28 | -0.38 | - | -0.3 | 1.32 |